| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
46,110,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
2,865 |
Avg
Vol: |
2,857 |
| 52
Week Range: |
$0.1798 - $0.1798 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Oragenics is focused on developing antibiotics against infectious disease and developing treatments for oral mucositis. Co. is developing AG013, an oral rinsing solution system designed to deliver human Trefoil Factor 1 to protect and regenerate damaged mucosal lining of the oral cavity in connection with the treatment of Oral Mucositis and a product candidate, OG716, as an antibiotic, as well as other homolog antibiotic product candidates. Co.'s other product candidates include a weight loss candidate, LPT3-04, and a topical treatment to prevent dental carries which it refers to as SMaRT Replacement Therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
230,084 |
| Total Buy Value |
$0 |
$0 |
$0 |
$65,241 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
6 |
| Total Shares Sold |
0 |
3,500 |
3,500 |
714,336 |
| Total Sell Value |
$0 |
$12,488 |
$12,488 |
$139,604 |
| Total People Sold |
0 |
1 |
1 |
2 |
| Total Sell Transactions |
0 |
1 |
1 |
10 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Koski Robert C |
Director |
– • • |
2009-12-30 |
4 |
OE |
$0.10 |
$10,000 |
D/D |
100,000 |
2,100,000 |
|
- |
|
| Hillman Jeffrey D |
Chief Scientific Officer |
• • – |
2009-12-30 |
4 |
A |
$0.25 |
$54,063 |
D/D |
216,250 |
818,294 |
|
- |
|
| Koski Thomas L |
10% Owner |
– – • |
2009-12-30 |
4 |
OE |
$0.10 |
$100,000 |
D/D |
1,000,000 |
53,960,000 |
|
- |
|
| Koski Thomas L |
10% Owner |
– – • |
2009-12-30 |
4 |
B |
$0.25 |
$2,250,000 |
D/D |
9,000,000 |
52,960,000 |
2.45 |
- |
|
| Koski Christine L |
Director |
– • • |
2009-12-30 |
4 |
OE |
$0.10 |
$10,000 |
D/D |
100,000 |
2,100,000 |
|
- |
|
| Koski Thomas L |
10% Owner |
– – • |
2009-12-28 |
4 |
A |
$0.00 |
$0 |
I/I |
40,000 |
40,000 |
|
- |
|
| Koski Thomas L |
10% Owner |
– – • |
2009-12-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000,000 |
2,000,000 |
|
- |
|
| Koski Thomas L |
10% Owner |
– – • |
2009-12-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,040,000) |
43,960,000 |
|
- |
|
| Hillman Jeffrey D |
Chief Scientific Officer |
• • – |
2009-06-29 |
4 |
A |
$0.10 |
$45,656 |
D/D |
456,564 |
602,044 |
|
- |
|
| Bohunicky Brian John |
Chief Financial Officer |
• – – |
2009-06-29 |
4 |
A |
$0.10 |
$25,000 |
D/D |
250,000 |
250,000 |
|
- |
|
| Koski Thomas L |
10% Owner |
– – • |
2009-06-29 |
4 |
B |
$0.08 |
$4,000,000 |
D/D |
50,000,000 |
50,000,000 |
2.45 |
- |
|
| Hirsch David Brian |
President and CEO |
• • – |
2009-06-29 |
4 |
A |
$0.10 |
$100,000 |
D/D |
1,000,000 |
1,000,000 |
|
- |
|
| Zahradnik Robert T |
Chief Operating OfficerOfficer |
• – – |
2009-03-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
881,000 |
|
- |
|
| Hawes George T |
10% Owner |
– – • |
2008-06-12 |
4 |
B |
$0.45 |
$2,501,000 |
D/D |
5,557,778 |
11,483,545 |
2.45 |
- |
|
| Hawes George T |
Director |
– • • |
2008-02-29 |
4 |
B |
$0.44 |
$220,000 |
D/D |
500,000 |
5,925,767 |
3.92 |
- |
|
| Zahradnik Robert T |
Former CEO & President |
– – – |
2008-02-08 |
4 |
B |
$0.44 |
$27,500 |
D/D |
62,500 |
881,000 |
2.44 |
- |
|
| Hillman Jeffrey D |
Director |
• • • |
2008-02-08 |
4 |
B |
$0.44 |
$27,500 |
D/D |
62,500 |
4,202,394 |
3.23 |
- |
|
| Gury David J |
Director |
– • – |
2008-02-08 |
4 |
B |
$0.44 |
$27,500 |
D/D |
62,500 |
125,000 |
2.39 |
- |
|
| Hawes George T |
Director |
– • • |
2008-02-08 |
4 |
B |
$0.44 |
$66,000 |
D/D |
150,000 |
5,425,767 |
3.92 |
- |
|
| Hawes George T |
Director |
– • • |
2008-02-04 |
4 |
B |
$0.44 |
$258,500 |
D/D |
587,500 |
5,275,767 |
3.92 |
- |
|
| Hawes George T |
10% Owner |
– – • |
2007-08-08 |
4 |
B |
$0.25 |
$25,000 |
I/I |
100,000 |
105,000 |
1.5 |
- |
|
| Hawes George T |
10% Owner |
– – • |
2007-08-08 |
4 |
B |
$0.25 |
$275,000 |
D/D |
1,100,000 |
4,688,267 |
2.45 |
- |
|
| Evens Ronald P |
Director |
– • – |
2007-08-07 |
4 |
B |
$0.44 |
$50,000 |
D/D |
113,636 |
113,636 |
2.39 |
- |
|
| Hawes George T |
Director |
– • • |
2006-12-05 |
4 |
OE |
$0.60 |
$420,000 |
D/D |
700,000 |
3,588,267 |
|
- |
|
| Hillman Jeffrey D |
Chief Scientific Officer |
• • • |
2006-11-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,480 |
82,980 |
|
- |
|
273 Records found
|
|
Page 10 of 11 |
|
|
